Lantern Pharma Inc

NASDAQ:LTRNUnited States

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
-- Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. DALLAS--(BUSINESS WIRE)--October 31, 2024--

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
DALLAS--(BUSINESS WIRE)--October 23, 2024--
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY.

Lantern Pharma to Host & Participate in Two Public Webinars During October
-- Both webinars will highlight how RADR(R), Lantern's AI platform, has been used to advance their portfolio and the portfolio of their collaborators. -- On October 28th, Lantern's CEO Panna Sharma will participate in Tribe Public's webinar event "Leveraging Artificial Intelligence to Develop Therapies for Brain and Childhood Cancers". -- On October 30th, Lantern will host "Webinar Wednesday" featuring Andrew Mazar, Ph.D., COO of Actuate Therapeutics, to discuss how Lantern's AI platform aided in the accelerated development and biomarker analytics for Actuate's drug-candidate, Elragllusib. -- Lantern Pharma has received four Rare Pediatric Disease Designations (RPDD) and was also recently granted the FDA's Fast Track Designation in glioblastoma. DALLAS--(BUSINESS WIRE)--October 21, 2024--